Antoni Bayes-Genis, Paloma Gastelurrutia, Marta Monguió-Tortajada, Maria Luisa Cámara, Cristina Prat-Vidal, German Cediel, Luciano Rodríguez-Gómez, Albert Teis, Elena Revuelta-López, Gemma Ferrer-Curriu, Santiago Roura, Carolina Gálvez-Montón, Felipe Bisbal, Joaquim Vives, Anna Vilarrodona, Christian Muñoz-Guijosa, Sergi Querol
BACKGROUND: In preclinical studies, the use of double allogeneic grafts has shown promising results in promoting tissue revascularization, reducing infarct size, preventing adverse remodelling and fibrosis, and ultimately enhancing cardiac function. Building upon these findings, the safety of PeriCord, an engineered tissue graft consisting of a decellularised pericardial matrix and umbilical cord Wharton's jelly mesenchymal stromal cells, was evaluated in the PERISCOPE Phase I clinical trial (NCT03798353), marking its first application in human subjects...
March 14, 2024: EBioMedicine